Taysha Gene Therapies (TSHA) Assets Average (2020 - 2026)
Taysha Gene Therapies (TSHA) posted Assets Average of $321.8 million for Q1 2026, down 2.46% sequentially from $329.9 million in Q4 2025, and up 115.47% YoY from $149.4 million in Q1 2025.
Taysha Gene Therapies (TSHA) Assets Average (2020 - 2026) Analysis & Trends
Taysha Gene Therapies has reported Assets Average for 7 years, with the latest figure at $321.8 million in Q1 2026.
- Quarterly Assets Average rose 115.47% year-over-year to $321.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $321.8 million (up 115.47% YoY) and the FY2025 annual result came in at $251.8 million, up 51.21% from the prior year.
- Assets Average slipped to $321.8 million in Q1 2026 per TSHA's latest filing, from $329.9 million in the prior quarter.
- Over five years, Assets Average peaked at $329.9 million in Q4 2025 and troughed at $91.6 million in Q2 2023.
- A 5-year average of $187.1 million and a median of $170.3 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2026: Assets Average plunged 47.75% in 2022, then surged 115.47% in 2026.
- Over 5 years, Assets Average stood at $118.9 million in 2022, then soared by 55.0% to $184.2 million in 2023, then slipped by 7.58% to $170.3 million in 2024, then jumped by 93.75% to $329.9 million in 2025, then fell by 2.46% to $321.8 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $321.8 million, $329.9 million, and $324.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Taysha Gene Therapies | 1.94 Bn | 1.94 Bn | - | 385.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 385.39 Mn |
| Mar 31, 2026 | 321.84 Mn |
| Dec 31, 2025 | 329.94 Mn |
| Sep 30, 2025 | 324.94 Mn |
| Jun 30, 2025 | 235.85 Mn |
| Mar 31, 2025 | 149.36 Mn |
| Dec 31, 2024 | 170.29 Mn |
| Sep 30, 2024 | 190.31 Mn |
| Jun 30, 2024 | 176.70 Mn |
| Mar 31, 2024 | 162.87 Mn |
| Dec 31, 2023 | 184.25 Mn |
| Sep 30, 2023 | 138.66 Mn |
| Jun 30, 2023 | 91.57 Mn |
| Mar 31, 2023 | 113.94 Mn |
| Dec 31, 2022 | 118.87 Mn |
| Sep 30, 2022 | 126.90 Mn |
| Jun 30, 2022 | 154.15 Mn |
| Mar 31, 2022 | 189.97 Mn |
| Dec 31, 2021 | 227.50 Mn |
| Sep 30, 2021 | 241.45 Mn |